Key facts
- This page summarizes Stephen P. Squinto's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 May 2022, 17:44.
Stephen P. Squinto - 19 May 2022 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- SWTX
- Reported as of
- 19 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 May 2022, 17:44:52 UTC
- Prior SEC filing
- 23 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis I. Perier, Jr as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen P. Squinto filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 20 May 2022.
Change
- Previous filing in this sequence was filed on 23 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,818
- Change %
- +3.8%
- Price
- $0.000000
- Shares after
- 131,652
- Date
- 19 May 2022
- Ownership
- Direct
- Footnotes
- F1
SWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,186,307
- Date
- 19 May 2022
- Ownership
- See Footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SWTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,318
- Change %
- Price
- $0.000000
- Shares after
- 15,318
- Date
- 19 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,318
- Exercise price
- $35.42
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Footnote F2
Shares held by OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OrbiMed VI. OrbiMed Advisors, LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Footnote F3
This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
Footnote F4
The options shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.